Boost Your Dermatology Studies: 5 Operational Essentials

Lori Lombardo, VP & Therapeutic Area Leader, Dermatology and General Medicine

Dermatology studies demand careful planning and precise execution to ensure the reliability and validity of research outcomes. This blog highlights five key operational considerations that can greatly enhance the success of dermatology clinical research. By addressing these factors, drug developers can streamline operational efficiency, safeguard data integrity, and achieve their study objectives more effectively.

 

1. Incorporate Innovative Thinking

Dermatology studies demand creative and tailored strategies to address the unique challenges and opportunities inherent in the field. By fostering a mindset of out-of-the-box thinking, researchers can develop more impactful study designs, improve patient engagement, and ultimately drive enhanced study outcomes. Designing the study with the patient in mind to reduce the patient burden will aid in patient recruitment. For example, ensuring the necessary in-clinic visits are supplemented by remote visits, or reducing the need for biopsies throughout the study.

 

2. Promote Rater Consistency to Ensure Reliability and Validity

Rater consistency is vital for ensuring the reliability and validity of research findings, as rater results are typically a primary endpoint. Promoting rater consistency involves:

  • Deploying Rater Training Materials: Help ensure raters are well-versed in the assessment criteria with comprehensive training programs.
  • Managing Vendors: Partner with reliable vendors to help provide standardized and high-quality training and support along with qualified central readers.
  • Tracking Performance: Regularly monitor rater performance across visits to identify and address any inconsistencies and intra-rater variability. Vendor experience in masking and de-identifying patient images is critical.

 

3. Address Rate-Limiting Factors During the Proposal Process

A dermatology clinical trial can face several challenges in the study startup phase. Drug development sponsors must ensure they have a plan for:

  • Creating Intuitive ePro Questionnaires: Ensure electronic patient-reported outcome (ePro) questionnaires are intuitive, patient-friendly, and comply with regulatory standards because many responses in dermatology studies are subjective, well-designed questionnaires are critical.
  • Securing All Licenses: Obtain all necessary licenses and permissions for using specific validated scales and patient or investigator questionnaires. This rate-limiting step should be addressed as early as possible upon study initiation.
  • Ensuring Accurate Translations: Offer linguistically accurate and culturally relevant translations of study materials to facilitate clear and effective communication with participants.

 

4. Optimize Your Timeline for Effective Planning and Management

Effective planning and management of the study timeline are critical to the success of dermatology studies. Key strategies include:

  • Accelerating Study Start-Up: Streamline the dermatology study start-up process by utilizing a comprehensive library of site documents and contract templates— dermatology-specific where applicable—which also help boost investigator engagement.  
  • Leveraging an Investigator Network: Leverage an established network of dermatology investigators and study sites   to minimize site qualification visits, thereby expediting the overall start-up process. Sponsors should also ensure the appropriate collaborations are in place for study needs.  For example, a study of radiation dermatitis will require a dermatologist as the primary investigator and a radiation oncologist as the sub-investigator.

 

5. Reduce Source Data Verification to Enhance Efficiency and Cost-Effectiveness

Reducing source data verification (SDV) is vital for enhancing the efficiency and cost-effectiveness of dermatology studies. Utilizing a central monitoring process, powered by a risk-based monitoring tool, offers several advantages, such as:

  • Identifying Trends and Outliers: Detect trends and outliers in data using centralized review, ensuring that specific data points, such as lab values, are not redundantly verified in electronic case report forms (eCRFs).
  • Reducing Duplication of Work: Minimize the need for redundant data verification, saving time and resources.
  • Lowering Costs: Reduce site and study costs by streamlining the data collection process.

 

Drive Your Dermatology Study with a Fit-for-Purpose Approach

Improving the effectiveness and reliability of dermatology studies requires a personalized approach that promotes innovative thinking and ensures rater consistency. Sponsors should plan ahead to address common challenges faced in study start-up, optimize their timelines, and increase efficiencies in monitoring to deliver quality data.

 

Set up a time to speak with one of our dermatology experts and learn about our solutions for advancing your study.

You might also be interested in

理解与应用欧盟临床试验法规(EU CTR) ——助力顺利推进临床试验申报

10/29/25

《欧盟临床试验法规》(EU CTR 536/2014)及其配套系统“临床试...

Read more

中国生物医药企业拓展欧洲临床试验的监管挑战

10/27/25

为帮助企业系统了解欧盟临床监管框架,康缔亚推出了九篇系列博...

Read more

Emerging Immunotherapy Combinations and Novel Approaches for Oncology and Hematology: Keys to Designing and Operationalizing Your Trial

10/14/25

The past decade has seen immunotherapy shift from a promis...

Read more
引领创新

康缔亚最新动态

探索我们的新闻动态,体验卓越服务品质

09/19/2025

康缔亚宣布彭彬博士出任科学顾问委员会主席

美国北卡罗来纳州罗利市,2025年9月19日——全球领先的临床合同研究组织(CRO)康缔亚(Caidya)宣布,正式聘任彭彬博士为公司科学顾问委员会主席。 彭博士将领导康缔亚科学顾问委员会,整合...

07/23/2025

康缔亚王军当选中国CDISC C3C主席;Medidata认证彰显卓越数据管理实力

美国北卡罗来纳州罗利市,2025年7月22日——全球技术驱动型研究服务供应商(CRO)康缔亚(Caidya)今日宣布,其编程高级总监王军(John Wang)被任命为国际临床数据交换标准协会(CDIS...

03/18/2025

Caidya(康缔亚)加强治疗领域领导力,任命Adam Callahan为肿瘤学和血液学负责人

2025年3月13日, 美国北卡罗来纳州罗利——全球领先的中型临床合同研究组织(CRO)康缔亚,今天宣布任命Adam Callahan为负责全球肿瘤学与血液学临床开发领域的副总裁。在这一职位上,他将为...
Skip to toolbar